Application of the ALBI Scoring System for Mortality Outcome Prediction in Patients with Hypertrophic Cardiomyopathy

Ping Qiao; Liying Li; Haiyan Ruan; Muxin Zhang; Ziqiong Wang; Xinran Li; Rufeng Shi; Xin Wei; Linjia Duan; Yi Zheng; Sen He

doi:10.5334/gh.1163

Application of the ALBI Scoring System for Mortality Outcome Prediction in Patients with Hypertrophic Cardiomyopathy

Volume 17 (2022): Issue 1

By: Ping Qiao , Liying Li , Haiyan Ruan , Muxin Zhang , Ziqiong Wang , Xinran Li, Rufeng Shi , Xin Wei, Linjia Duan, Yi Zheng and Sen He

Open Access

|Oct 2022

Abstract

Background: There is no information about the clinical significance of the albumin-bilirubin (ALBI) score in patients with hypertrophic cardiomyopathy (HCM).

Objective: We retrospectively performed clinical evaluations in 462 patients with HCM to estimate whether the ALBI score could be a new tool to predict mortality in HCM.

Methods and Results: During a median follow-up of 4.7 years, HCM-related death occurred in 52 (11.3%) patients. Overall, there was a significant positive association between ALBI score and HCM-related death (adjusted hazard ratio [HR]: 1.79 per one standard deviation [SD] increment, 95% confidence interval [CI]: 1.36–2.35). When the score was assessed as tertiles, the adjusted HRs of HCM-related death were 1.30 (95% CI: 0.42–3.99) for the tertile 2 and 4.43 (95% CI: 1.65–11.89) for the tertile 3, compared with the tertile 1. Stratified analysis and E-value analysis suggested the robustness of the above-mentioned results. Meanwhile, time-dependent ROC analysis showed ALBI score could discriminate HCM-related death at various time points (AUC ranges: 0.725–0.850). Furthermore, exploratory analysis indicated the dynamic changes of ALBI score also could predict HCM-related death. Finally, multiple linear regression analysis suggested some pathogenetic pathways associated with HCM-related adverse outcomes significantly correlated with ALBI score, and the pathways included inflammation, myocardial injury, nutritional status and some clinical characteristics, but not abnormal cardiac structure and function itself.

Conclusions: Higher ALBI score is a strong independent predictor of HCM-related death in patients with HCM.

References

Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med. 2018; 379(7): 655–68. DOI: 10.1056/NEJMra1710575
Open DOI Search in Google Scholar Back to article
Maron BJ, Maron MS, Rowin EJ. Perspectives on the Overall Risks of Living With Hypertrophic Cardiomyopathy. Circulation. 2017; 135(24): 2317–9. DOI: 10.1161/CIRCULATIONAHA.117.027738
Open DOI Search in Google Scholar Back to article
Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018; 138(14): 1387–98. DOI: 10.1161/CIRCULATIONAHA.117.033200
Open DOI Search in Google Scholar Back to article
Pujades-Rodriguez M, Guttmann OP, Gonzalez-Izquierdo A, Duyx B, O’Mahony C, Elliott P, et al. Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records. PLoS One. 2018; 13(1): e0191214. DOI: 10.1371/journal.pone.0191214
Open DOI Search in Google Scholar Back to article
Lorenzini M, Anastasiou Z, O’Mahony C, Guttman OP, Gimeno JR, Monserrat L, et al. Mortality Among Referral Patients with Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiol. 2020; 5(1): 73–80. DOI: 10.1001/jamacardio.2019.4534
Open DOI Search in Google Scholar Back to article
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015; 33(6): 550–8. DOI: 10.1200/JCO.2014.57.9151
Open DOI Search in Google Scholar Back to article
Abdel-Rahman O. Prognostic Value of Baseline ALBI Score Among Patients with Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials. Clin Colorectal Cancer. 2019; 18(1): e61–e8. DOI: 10.1016/j.clcc.2018.09.008
Open DOI Search in Google Scholar Back to article
Bernardi N, Chedid MF, Grezzana-Filho TJM, Chedid AD, Pinto MA, Leipnitz I, et al. Pre-transplant ALBI Grade 3 Is Associated with Increased Mortality After Liver Transplantation. Dig Dis Sci. 2019; 64(6): 1695–704. DOI: 10.1007/s10620-019-5456-6
Open DOI Search in Google Scholar Back to article
Oikonomou T, Goulis L, Doumtsis P, Tzoumari T, Akriviadis E, Cholongitas E. ALBI and PALBI Grades Are Associated with the Outcome of Patients with Stable Decompensated Cirrhosis. Ann Hepatol. 2019; 18(1): 126–36. DOI: 10.5604/01.3001.0012.7904
Open DOI Search in Google Scholar Back to article
Imamura T, Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, et al. Clinical Significance of Preoperative Albumin-Bilirubin Grade in Pancreatic Cancer. Ann Surg Oncol. 2021. DOI: 10.1245/s10434-021-09593-9
Open DOI Search in Google Scholar Back to article
Kim MS, Kato TS, Farr M, Wu C, Givens RC, Collado E, et al. Hepatic dysfunction in ambulatory patients with heart failure: application of the MELD scoring system for outcome prediction. J Am Coll Cardiol. 2013; 61(22): 2253–61. DOI: 10.1016/j.jacc.2012.12.056
Open DOI Search in Google Scholar Back to article
Boon AC, Bulmer AC, Coombes JS, Fassett RG. Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. Am J Physiol Renal Physiol. 2014; 307(2): F123–36. DOI: 10.1152/ajprenal.00039.2014
Open DOI Search in Google Scholar Back to article
Targher G, Byrne CD. Circulating Markers of Liver Function and Cardiovascular Disease Risk. Arterioscler Thromb Vasc Biol. 2015; 35(11): 2290–6. DOI: 10.1161/ATVBAHA.115.305235
Open DOI Search in Google Scholar Back to article
Kawata T, Ikeda A, Masuda H, Komatsu S. Association Between Albumin-Bilirubin Score at Admission and In-Hospital Mortality in Patients with Acute Heart Failure. Int Heart J. 2021; 62(4): 829–36. DOI: 10.1536/ihj.21-080
Open DOI Search in Google Scholar Back to article
Matsue Y, Kagiyama N, Yamaguchi T, Kuroda S, Okumura T, Kida K, et al. Clinical and Prognostic Values of ALBI Score in Patients with Acute Heart Failure. Heart Lung Circ. 2020; 29(9): 1328–37. DOI: 10.1016/j.hlc.2019.12.003
Open DOI Search in Google Scholar Back to article
Kunutsor SK, Bakker SJ, Gansevoort RT, Chowdhury R, Dullaart RP. Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol. 2015; 35(3): 716–24. DOI: 10.1161/ATVBAHA.114.304929
Open DOI Search in Google Scholar Back to article
Arques S. Human serum albumin in cardiovascular diseases. Eur J Intern Med. 2018; 52: 8–12. DOI: 10.1016/j.ejim.2018.04.014
Open DOI Search in Google Scholar Back to article
Lamke GT, Allen RD, Edwards WD, Tazelaar HD, Danielson GK. Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy. Cardiovascular Pathology. 2003; 12(3): 149–58. DOI: 10.1016/S1054-8807(03)00036-X
Open DOI Search in Google Scholar Back to article
Nakamura K, Kusano KF, Matsubara H, Nakamura Y, Miura A, Nishii N, et al. Relationship Between Oxidative Stress and Systolic Dysfunction in Patients with Hypertrophic Cardiomyopathy. Journal of Cardiac Failure. 2005; 11(2): 117–23. DOI: 10.1016/j.cardfail.2004.05.005
Open DOI Search in Google Scholar Back to article
Dimitrow PP, Undas A, Wołkow P, Tracz W, Dubiel JS. Enhanced oxidative stress in hypertrophic cardiomyopathy. Pharmacological Reports. 2009; 61(3): 491–5. DOI: 10.1016/S1734-1140(09)70091-X
Open DOI Search in Google Scholar Back to article
Kuusisto J, Karja V, Sipola P, Kholova I, Peuhkurinen K, Jaaskelainen P, et al. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart. 2012; 98(13): 1007–13. DOI: 10.1136/heartjnl-2011-300960
Open DOI Search in Google Scholar Back to article
Becker RC, Owens AP, 3rd, Sadayappan S. Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy. J Thromb Thrombolysis. 2020; 49(2): 177–83. DOI: 10.1007/s11239-019-02026-1
Open DOI Search in Google Scholar Back to article
Authors/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35(39): 2733–79. DOI: 10.1093/eurheartj/ehu284
Open DOI Search in Google Scholar Back to article
Wang Z, Zhao L, He S. Prognostic nutritional index and the risk of mortality in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2021; 331: 152–7. DOI: 10.1016/j.ijcard.2021.01.023
Open DOI Search in Google Scholar Back to article
Liao H, Wang Z, Zhao L, Chen X, He S. Myocardial contraction fraction predicts mortality for patients with hypertrophic cardiomyopathy. Sci Rep. 2020; 10(1): 17026. DOI: 10.1038/s41598-020-72712-1
Open DOI Search in Google Scholar Back to article
He S, Wang Z, Cheem TH, Liao H, Chen X, He Y. External Validation of the Model of Thromboembolic Risk in Hypertrophic Cardiomyopathy Patients. Can J Cardiol. 2019; 35(12): 1800–6. DOI: 10.1016/j.cjca.2019.05.035
Open DOI Search in Google Scholar Back to article
Ho HH, Lee KL, Lau CP, Tse HF. Clinical characteristics of and long-term outcome in Chinese patients with hypertrophic cardiomyopathy. Am J Med. 2004; 116(1): 19–23. DOI: 10.1016/j.amjmed.2003.09.020
Open DOI Search in Google Scholar Back to article
Lee CH, Liu PY, Lin LJ, Chen JH, Tsai LM. Clinical characteristics and outcomes of hypertrophic cardiomyopathy in Taiwan--a tertiary center experience. Clin Cardiol. 2007; 30(4): 177–82. DOI: 10.1002/clc.20057
Open DOI Search in Google Scholar Back to article
Songsirisuk N, Kittipibul V, Methachittiphan N, Charoenattasil V, Zungsontiporn N, Spanuchart I, et al. Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand. BMC Cardiovascular Disorders. 2019; 19(1). DOI: 10.1186/s12872-018-0984-0
Open DOI Search in Google Scholar Back to article
Coats CJ, Gallagher MJ, Foley M, O’Mahony C, Critoph C, Gimeno J, et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur Heart J. 2013; 34(32): 2529–37. DOI: 10.1093/eurheartj/eht070
Open DOI Search in Google Scholar Back to article
Haruki S, Minami Y, Hagiwara N. Stroke and Embolic Events in Hypertrophic Cardiomyopathy: Risk Stratification in Patients Without Atrial Fibrillation. Stroke. 2016; 47(4): 936–42. DOI: 10.1161/STROKEAHA.115.012130
Open DOI Search in Google Scholar Back to article
Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: identification of high-risk patients. J Am Coll Cardiol. 2000; 36(7): 2212–8. DOI: 10.1016/S0735-1097(00)01003-2
Open DOI Search in Google Scholar Back to article
Liu Q, Li D, Berger AE, Johns RA, Gao L. Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis. Sci Rep. 2017; 7(1): 11957. DOI: 10.1038/s41598-017-12289-4
Open DOI Search in Google Scholar Back to article
Haneuse S, VanderWeele TJ, Arterburn D. Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies. JAMA. 2019; 321(6): 602–3. DOI: 10.1001/jama.2018.21554
Open DOI Search in Google Scholar Back to article
Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination and Calibration of Clinical Prediction Models: Users’ Guides to the Medical Literature. JAMA. 2017; 318(14): 1377–84. DOI: 10.1001/jama.2017.12126
Open DOI Search in Google Scholar Back to article
Hogye M, Mandi Y, Csanady M, Sepp R, Buzas K. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol. 2004; 94(2): 249–51. DOI: 10.1016/j.amjcard.2004.03.078
Open DOI Search in Google Scholar Back to article
Zen K, Irie H, Doue T, Takamiya M, Yamano T, Sawada T, et al. Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy. Int Heart J. 2005; 46(2): 231–44. DOI: 10.1536/ihj.46.231
Open DOI Search in Google Scholar Back to article
Iwasaki J, Nakamura K, Matsubara H, Nakamura Y, Nishii N, Banba K, et al. Relationship between circulating levels of monocyte chemoattractant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol. 2009; 18(6): 317–22. DOI: 10.1016/j.carpath.2008.12.004
Open DOI Search in Google Scholar Back to article
Zhu L, Zou Y, Wang Y, Luo X, Sun K, Wang H, et al. Prognostic Significance of Plasma High-Sensitivity C-Reactive Protein in Patients with Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2017; 6(2). DOI: 10.1161/JAHA.116.004529
Open DOI Search in Google Scholar Back to article
Christiansen LB, Dela F, Koch J, Hansen CN, Leifsson PS, Yokota T. Impaired cardiac mitochondrial oxidative phosphorylation and enhanced mitochondrial oxidative stress in feline hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2015; 308(10): H1237–47. DOI: 10.1152/ajpheart.00727.2014
Open DOI Search in Google Scholar Back to article
Brites D. Bilirubin injury to neurons and glial cells: new players, novel targets, and newer insights. Semin Perinatol. 2011; 35(3): 114–20. DOI: 10.1053/j.semperi.2011.02.004
Open DOI Search in Google Scholar Back to article
Wiedermann CJ. Anti-inflammatory activity of albumin. Crit Care Med. 2007; 35(3): 981–2; author reply 2–3. DOI: 10.1097/01.CCM.0000257234.87784.91
Open DOI Search in Google Scholar Back to article
Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008; 582(13): 1783–7. DOI: 10.1016/j.febslet.2008.04.057
Open DOI Search in Google Scholar Back to article
Afari ME, Bhat T. Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update. Expert Rev Cardiovasc Ther. 2016; 14(5): 573–7. DOI: 10.1586/14779072.2016.1154788
Open DOI Search in Google Scholar Back to article
Katipoglu Z, Mirza E, Oltulu R, Katipoglu B. May Monocyte/HDL Cholesterol Ratio (MHR) and Neutrophil/Lymphocyte Ratio (NLR) Be an Indicator of Inflammation and Oxidative Stress in Patients with Keratoconus? Ocul Immunol Inflamm. 2020; 28(4): 632–6. DOI: 10.1080/09273948.2019.1611876
Open DOI Search in Google Scholar Back to article
Kubo T, Kitaoka H, Yamanaka S, Hirota T, Baba Y, Hayashi K, et al. Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013; 62(14): 1252–9. DOI: 10.1016/j.jacc.2013.03.055
Open DOI Search in Google Scholar Back to article
Kehl DW, Buttan A, Siegel RJ, Rader F. Clinical utility of natriuretic peptides and troponins in hypertrophic cardiomyopathy. Int J Cardiol. 2016; 218: 252–8. DOI: 10.1016/j.ijcard.2016.05.031
Open DOI Search in Google Scholar Back to article
Tardiff JC, Carrier L, Bers DM, Poggesi C, Ferrantini C, Coppini R, et al. Targets for therapy in sarcomeric cardiomyopathies. Cardiovascular Research. 2015; 105(4): 457–70. DOI: 10.1093/cvr/cvv023
Open DOI Search in Google Scholar Back to article
Kundur AR, Singh I, Bulmer AC. Bilirubin, platelet activation and heart disease: a missing link to cardiovascular protection in Gilbert’s syndrome? Atherosclerosis. 2015; 239(1): 73–84. DOI: 10.1016/j.atherosclerosis.2014.12.042
Open DOI Search in Google Scholar Back to article
Iba T, Hamakubo T, Nagaoka I, Sato K, Thachil J. Physiological Levels of Pentraxin 3 and Albumin Attenuate Vascular Endothelial Cell Damage Induced by Histone H3 In Vitro. Microcirculation. 2016; 23(3): 240–7. DOI: 10.1111/micc.12269
Open DOI Search in Google Scholar Back to article
McCullough SA, Fifer MA, Mohajer P, Lowry PA, Reen CO, Baggish AL, et al. Clinical Correlates and Prognostic Value of Elevated Right Atrial Pressure in Patients with Hypertrophic Cardiomyopathy. Circ J. 2018; 82(5): 1405–11. DOI: 10.1253/circj.CJ-17-0959
Open DOI Search in Google Scholar Back to article
Lee HJ, Kim HK, Kim M, Moon I, Lee H, Kim BS, et al. Clinical impact of atrial fibrillation in a nationwide cohort of hypertrophic cardiomyopathy patients. Ann Transl Med. 2020; 8(21): 1386. DOI: 10.21037/atm-20-1817
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.5334/gh.1163 | Journal eISSN: 2211-8179

Journal RSS Feed

Language: English

Submitted on: Apr 17, 2022

Accepted on: Sep 21, 2022

Published on: Oct 11, 2022

Published by: Ubiquity Press

In partnership with: Paradigm Publishing Services

Publication frequency: 1 issue per year

Keywords:

albumin,

bilirubin,

mortality,

hypertrophic cardiomyopathy

© 2022 Ping Qiao, Liying Li, Haiyan Ruan, Muxin Zhang, Ziqiong Wang, Xinran Li, Rufeng Shi, Xin Wei, Linjia Duan, Yi Zheng, Sen He, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 17 (2022): Issue 1